Chardan Capital Issues Pessimistic Forecast for Silence Therapeutics (NASDAQ:SLN) Stock Price

Silence Therapeutics (NASDAQ:SLN - Free Report) had its target price decreased by Chardan Capital from $55.00 to $35.00 in a report released on Friday morning,Benzinga reports. Chardan Capital currently has a buy rating on the stock.

A number of other equities research analysts also recently weighed in on the company. BMO Capital Markets cut their target price on Silence Therapeutics from $67.00 to $25.00 and set an "outperform" rating for the company in a research report on Tuesday, March 4th. The Goldman Sachs Group reduced their price target on Silence Therapeutics from $6.00 to $4.00 and set a "sell" rating for the company in a report on Tuesday, March 4th. HC Wainwright reiterated a "buy" rating and set a $75.00 price target on shares of Silence Therapeutics in a research note on Friday, March 7th. Finally, Morgan Stanley cut their price target on Silence Therapeutics from $49.00 to $45.00 and set an "overweight" rating for the company in a report on Wednesday, March 5th. One analyst has rated the stock with a sell rating and six have given a buy rating to the company's stock. According to data from MarketBeat.com, Silence Therapeutics has a consensus rating of "Moderate Buy" and an average target price of $33.83.

Silence Therapeutics Price Performance

NASDAQ:SLN traded down $0.06 on Friday, reaching $4.05. The stock had a trading volume of 90,716 shares, compared to its average volume of 298,467. The company has a market cap of $121.22 million, a price-to-earnings ratio of -2.58 and a beta of 1.20. Silence Therapeutics has a 12-month low of $1.97 and a 12-month high of $24.38. The firm's fifty day moving average is $3.36 and its two-hundred day moving average is $6.30.

Silence Therapeutics (NASDAQ:SLN - Get Free Report) last posted its earnings results on Thursday, May 8th. The company reported ($0.60) EPS for the quarter, missing analysts' consensus estimates of ($0.18) by ($0.42). Silence Therapeutics had a negative return on equity of 62.81% and a negative net margin of 342.00%. The firm had revenue of $0.14 million for the quarter, compared to analyst estimates of $3.58 million. As a group, research analysts forecast that Silence Therapeutics will post -1.77 earnings per share for the current fiscal year.

Institutional Trading of Silence Therapeutics

Several hedge funds have recently bought and sold shares of SLN. Redmile Group LLC increased its stake in shares of Silence Therapeutics by 26.3% during the 4th quarter. Redmile Group LLC now owns 2,399,317 shares of the company's stock worth $16,507,000 after purchasing an additional 500,000 shares during the last quarter. Nantahala Capital Management LLC increased its position in shares of Silence Therapeutics by 424.8% during the fourth quarter. Nantahala Capital Management LLC now owns 1,049,676 shares of the company's stock valued at $7,222,000 after buying an additional 849,676 shares during the period. Point72 Asset Management L.P. grew its stake in Silence Therapeutics by 35.3% in the fourth quarter. Point72 Asset Management L.P. now owns 633,100 shares of the company's stock worth $4,356,000 after purchasing an additional 165,300 shares during the period. Cantor Fitzgerald L. P. boosted its holdings in Silence Therapeutics by 61.5% in the fourth quarter. Cantor Fitzgerald L. P. now owns 539,726 shares of the company's stock worth $3,713,000 after acquiring an additional 205,534 shares in the last quarter. Finally, Bank of America Corp DE increased its position in shares of Silence Therapeutics by 48,165.6% during the fourth quarter. Bank of America Corp DE now owns 499,066 shares of the company's stock valued at $3,434,000 after acquiring an additional 498,032 shares in the last quarter. Institutional investors and hedge funds own 98.73% of the company's stock.

About Silence Therapeutics

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver.